Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

Kakkar, 1975, Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial, Lancet, 2, 45

1986, Prevention of venous thrombosis and pulmonary embolism, NIH consensus statement, 6, 1

Shojania

Geerts, 2004, Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 338S, 10.1378/chest.126.3_suppl.338S

2002

Eikelboom, 2001, Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials, Lancet, 358, 9, 10.1016/S0140-6736(00)05249-1

Hull, 2001, Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review, Ann Intern Med, 135, 858, 10.7326/0003-4819-135-10-200111200-00006

Warwick, 2007, Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry, J Bone Joint Surg Br, 89, 799, 10.1302/0301-620X.89B6.18844

2000, Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial, Lancet, 355, 1295, 10.1016/S0140-6736(00)02110-3

Anderson, 2003, Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996–2001: findings from the Hip and Knee Registry, Chest, 124, 349S, 10.1378/chest.124.6_suppl.349S

Callaghan, 2005, Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians—are they appropriate for orthopaedic surgery?, J Arthroplasty, 20, 273, 10.1016/j.arth.2005.01.014

White, 1998, Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty, Arch Intern Med, 158, 1525, 10.1001/archinte.158.14.1525

Friedman, 2007, Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty, J Am Acad Orthop Surg, 15, 148, 10.5435/00124635-200703000-00004

Eriksson, 2006, A once-daily, oral, direct factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement, Circulation, 114, 2374, 10.1161/CIRCULATIONAHA.106.642074

Eriksson, 2006, Oral, direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement, J Thromb Haemost, 4, 121, 10.1111/j.1538-7836.2005.01657.x

Eriksson, 2007, Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement, Thromb Res, 120, 685, 10.1016/j.thromres.2006.12.025

Rabinov, 1972, Roentgen diagnosis of venous thrombosis in the leg, Arch Surg, 104, 134, 10.1001/archsurg.1972.04180020014004

Bergqvist, 1996, Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement, N Engl J Med, 335, 696, 10.1056/NEJM199609053351002

Lassen, 1998, Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty—the Danish Prolonged Prophylaxis (DaPP) Study, Thromb Res, 89, 281, 10.1016/S0049-3848(98)00018-8

Comp, 2001, Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group, J Bone Joint Surg Am, 83-A, 336, 10.2106/00004623-200103000-00004

Prandoni, 2002, Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study, Arch Intern Med, 162, 1966, 10.1001/archinte.162.17.1966

Dahl, 1997, Prolonged thromboprophylaxis following hip replacement surgery—results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin), Thromb Haemost, 77, 26, 10.1055/s-0038-1655901

Hull, 2000, Low-molecular-weight heparin prophylaxis using extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind randomized comparison. North American Fragmin Trial Investigators, Arch Intern Med, 160, 2208, 10.1001/archinte.160.14.2208

Planes, 1996, Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo, Lancet, 348, 224, 10.1016/S0140-6736(96)01453-5

Eriksson, 2007, Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: the RECORD1 trial, Blood, 110, 10.1182/blood.V110.11.6.6

Lassen, 2007, Rivaroxaban – an oral, direct factor Xa inhibitor – for thromboprophylaxis after total knee arthroplasty: the RECORD3 trial, Blood, 110, 10.1182/blood.V110.11.308.308

Rosencher, 2003, Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe, Transfusion, 43, 459, 10.1046/j.1537-2995.2003.00348.x

Dahl, 2004, Orthopaedic surgery as a model for drug development in thrombosis, Drugs, 64, 17, 10.2165/00003495-200464001-00004

Kakkar, 2004, Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines, J Thromb Haemost, 2, 221, 10.1111/j.1538-7933.2004.00588.x